FDA Updates SMA Treatment Dosing - Top-Institutions - MDSpire

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

  • By

  • Kathryn Wighton

  • March 30, 2026

  • 2 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Children's Hospital of Philadelphia
    Children's Hospital of Philadelphia

    Philadelphia, PA

    Key Differentiators

    • Neurology
    • Pediatric Neurology
    • Neuromuscular Disorders

  • #2

    Nationwide Children's Hospital
    Nationwide Children's Hospital

    Columbus, OH

    Key Differentiators

    • Neurology
    • Pediatric Neurology
    • Neuromuscular Disorders

  • #3

    Washington University School of Medicine
    Washington University School of Medicine

    St. Louis, MO

    Key Differentiators

    • Neurology
    • Neuromuscular Disorders
    • Genetics

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Neuromuscular Disorders
    • Pediatric Neurology

Original Source(s)

FDA Updates SMA Treatment Dosing

  • by Kathryn Wighton

  • March 30, 2026

Related Content

Symptom Scores May Signal Neuropathy Risk

Early recovery symptom patterns may help clinicians identify which oropharyngeal cancer survivors warrant closer neurologic surveillance.

Perampanel use in pediatric autoimmune encephalitis-related seizures and epilepsy: a retrospective case series

MRI May Define Two Distinct Migraine Phenotypes

Patients with greater migraine burden showed widespread connectivity changes and lower cortical volume.